Futuristic Approaches That Reduce Treatment Burden in Age-related Macular Degeneration and Diabetic Macular Edema

Author(s)/Faculty: Caroline Baumal, MD; Christina Y. Weng, MD, MBA
Release Date: 10/7/2021Expiration Date: 10/6/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Anti-vascular endothelial growth factor (anti-VEGF) therapy has been the mainstay in the treatment of patients with age-related macular degeneration (AMD) and diabetic macular edema (DME). However, despite the significant visual gains reported in clinical trials with these agents, real-world experience shows that outcomes are often suboptimal, mainly due to inconsistent patient adherence to treatment schedules. As such, to ensure that these patients achieve optimal clinical outcomes and visual gains, therapies with longer duration of action are required, especially if these approaches can lengthen the time between treatment. In this activity, expert faculty explore the new and emerging therapies and treatment delivery systems that can extend duration of action while decreasing the frequency of treatments.